Autres langues Ildong Holdings Co., Ltd.

Actions

A000230

KR7000230003

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 03/07/2024			Varia. 5j.	Varia. 1 janv.
7 520 ^KRW	+0,53%		+2,87%	-28,52%

14/03	Ildong Holdings Co. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	Ildong Holdings Co. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Ildong Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Ildong Holdings Co., Ltd.(KOSE:A000230) dropped from S&P Global BMI Index	18/09/23
Ildong Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Shionogi & Co., Ltd. - New Drug Application of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19 Accepted for Review in South Korea	05/01/23
Idience Co., Ltd announced that it has received KRW 14.9949886 billion in funding from Ildong Holdings Co., Ltd.	30/12/22
Idience Co., Ltd announced that it expects to receive KRW 14.9949886 billion in funding from Ildong Holdings Co., Ltd.	21/12/22
Ildong Holdings Co., Ltd. announced that it has received KRW 30 billion in funding	30/11/22
Ildong Holdings Co., Ltd. announced that it expects to receive KRW 30 billion in funding	15/11/22
Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Ildong Holdings Co., Ltd.(KOSE:A000230) added to S&P Global BMI Index	19/09/22
Execution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Ildong for Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19, for South Korea	16/09/22
Ildong Holdings Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22
Twist Bioscience, Ildong Pharmaceutical Partner to Discover Antibodies for Immuno-Oncology	30/06/22
Idience Co., Ltd announced that it expects to receive KRW 15.0050118 billion in funding from Ildong Holdings Co., Ltd., Yuanta Investment, Kiwoom Securities Co., Ltd., Investment Arm and other investors	28/06/22
Ildong Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22
Ildong Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	17/03/22
Ildong : Prior Notice on Disclosure of Final Earnings	14/02/22
Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21
Ildong Holdings Co., Ltd. acquired 5.18% stake in Ildong Pharmaceutical Co., Ltd. from Il-dong Foods Co. Ltd. and Lee, Keumki for KRW 22.4 billion.	27/02/19

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ildong Holdings Co., Ltd.

Actions

A000230

KR7000230003

Autres langues

Filtres